<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324893</url>
  </required_header>
  <id_info>
    <org_study_id>16-5153</org_study_id>
    <nct_id>NCT03324893</nct_id>
  </id_info>
  <brief_title>FCH PET/MRI Parathyroid Localization</brief_title>
  <official_title>18F-Fluorocholine PET/MRI for the Localization of Parathyroid Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective trial comparing the accuracy of [F-18]-FCH PET/MRI to US and 99mTc-MIBI
      SPECT/CT for pre-operative parathyroid localization in patients with primary
      hyperparathyroidism
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of [F-18]-FCH PET/MRI in localization of diseased parathyroid gland</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>Value of [F-18]-FCH PET/MRI next to Ultrasound of the Neck and 99mTc-MIBI SPECT/CT in determining which of the four parathyroid glands
Reference standards:
Intra-operative location of the hyper functioning gland by inspection and post-operative pathological confirmation.
Determination of biochemical cure per usual standard of care: intraoperative PTH and calcium and PTH postoperatively.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>18F-fluorocholine</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Hyperparathyroidism, Primary</condition>
  <arm_group>
    <arm_group_label>[F18]-FCH PET/MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with primary hyperparathyroidism planned for parathyroidectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[F-18]-FCH PET/MRI</intervention_name>
    <description>Subjects will undergo the [F-18]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.</description>
    <arm_group_label>[F18]-FCH PET/MRI</arm_group_label>
    <other_name>FCH PET/MRI</other_name>
    <other_name>Fluorine-18 fluorocholine PET/MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Biochemically proven primary hyperparathyroidism

          -  Indication for parathyroidectomy as per institutional guidelines

        Exclusion Criteria:

          -  Contraindication for MRI as per current institutional guidelines.

          -  Contraindication for Gadolinium injection as per current institutional guidelines.

          -  Renal failure

          -  Inability to lie supine for at least 45 minutes.

          -  Any participant who is pregnant or breastfeeding.

          -  Participants receiving erythropoietin (i.e. for hemochromatosis; might lead to false
             negative results due to stimulation of bone marrow metabolism)

          -  Familial HPT syndromes

          -  Participant currently being treated with any cytotoxic chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jesse Pasternak, MD, MPHc FRCSC</last_name>
    <phone>+14163405195</phone>
    <email>jesse.pasternak@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Veit-Haibach, MD</last_name>
    <phone>+14169464501</phone>
    <phone_ext>5734</phone_ext>
    <email>patrick.veit-haibach@uhn.ca</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

